Jaguar health completes filing of new animal drug application for conditional approval of canalevia-ca1 (crofelemer) to treat chemotherapy-induced diarrhea in dogs, clearing way for december 2021 launch

Canalevia™-ca1 is the first and only oral plant-based prescription drug candidate for cid in dogs jaguar kicks off educational awareness contest in honor of international jaguar day; click here to enter san francisco, ca / accesswire / november 2, 2021 / jaguar health, inc. (nasdaq:jagx) today announced that it has completed the filing of the new animal drug application (nada) to request the u.s. food and drug administration's conditional approval to market canalevia™-ca1 (crofelemer delayed-release tablets), jaguar's oral plant-based prescription drug candidate for the treatment of chemotherapy-induced diarrhea (cid) in dogs. "all required major and minor technical sections of our application for conditional approval of canalevia for cid in dogs have been deemed ‘complete' by the cvm, and filing of the nada is an administrative activity that results in approval for commercialization 60 days later.
JAGX Ratings Summary
JAGX Quant Ranking